Microelectrode studies in toad urinary bladder epithelium. effects of Na concentration changes in the mucosal solution on equivalent electromotive forces

Microelectrode techniques were employed to measure membrane potentials, the electrical resistance of the cell membranes, and the shunt pathway, and to compute the equivalent electromotive forces (EMF) at both cell borders in toad urinary bladder epithelium before and after reductions in mucosal sodium concentration. Basal electrical parameters were not significantly different from those obtained with impalements from the serosal side, indicating that mucosal impalements do not produce significant leaks in the apical membrane. A decrease in mucosal Na concentration caused the cellular resistance to increase and both apical and basolateral EMF to depolarize. When Na was reduced from 112 to 2.4 mM in bladders with spontaneously different baseline values of transepithelial potential difference (Vms), a direct relationship was found between the change in Vms brought about by the Na reduction and the base-line Vms before the change. A direct relationship was also found by plotting the change in EMF at the apical or basolateral border caused by a mucosal Na reduction with the corresponding base-line EMF before the change. These results indicate that resting apical membrane EMF (and, therefore, resting apical membrane potential) is determined by the Na selectivity of the apical membrane, whereas basolateral EMF is at least in part the result of rheogenic Na transport. These results are consistent with data of others that suggested a link between the activity of the basolateral Na pump and apical Na conductance

Caracterización de una bomba de calor fotovoltaica con conexión a la red eléctrica para generación de frío

CIES2020 - XVII Congresso Ibérico e XIII Congresso Ibero-americano de Energia SolarRESUMEN: Este artículo describe los resultados de la caracterización técnica de un prototipo de bomba de calor fotovoltaica (BC-FV) hibridada con la red eléctrica, para aplicaciones de generación de frío para climatización de espacios. Esta caracterización se ha realizado con un algoritmo de control “inverter”, caracterizado por regular la frecuencia del compresor de la BC para mantener una temperatura de consigna en la habitación. Se han efectuado dos ensayos para dos temperaturas de consigna de 18 ºC y 24 ºC. Se han calculado indicadores de rendimiento del generador FV -PR, PRPV,CEM y 3 factores de utilización-, de la BC -EER y SPF- y de todo el conjunto del sistema -SFFV y SPFBC-FV,CEM, que se obtienen combinando todos los anteriores-. Los resultados muestran un buen comportamiento de los componentes del sistema. La calidad del acoplamiento entre ellos viene determinada fundamentalmente por el aprovechamiento del generador FV por parte del compresor que, a su vez, depende del dimensionado y de la temperatura de consigna establecida.ABSTRACT: This paper presents the results of the technical characterization of a photovoltaic heat pump (PV-HP) prototype connected to the electric grid, for space cooling applications. This characterization has been performed for an “inverter” control that regulates the frequency of the compressor for maintaining a certain temperature set point. Two test have been implemented for two different temperature set points, 18 ºC and 24 ºC. Several performance indicators have been calculated for the PV generator -PR, PRPV,CEM y 3 utilization ratios-, for the HP unit -EER y SPF- and for the whole system -SFFV y SPFBC-FV,CEM, which is obtained as a combination of all the others-. The results show a good performance of the system components. The quality of the coupling between them mosthly depends on the utilization of the PV generator, that is determined by the sizing of these components and by the temperature set point value.info:eu-repo/semantics/publishedVersio

Anion-sensitive sodium conductance in the apical membrane of toad urinary bladder

Membrane potentials and the electrical resistance of the cell membranes and the shunt pathway of toad urinary bladder epithelium were measured using microelectrode techniques. These measurements were used to compute the equivalent electromotive forces (EMF) at both cell borders before and after reductions in mucosal Cl- concentration ([Cl]m). The effects of reduction in [Cl]m depended on the anionic substitute. Gluconate or sulfate substitutions increased transepithelial resistance, depolarized membrane potentials and EMF at both cell borders, and decreased cell conductance. Iodide substitutions had opposite effects. Gluconate or sulfate substitutions decreased apical Na conductance, where iodide replacements increased it. When gluconate or sulfate substitutions were brought about the presence of amiloride in the mucosal solution, apical membrane potential and EMF hyperpolarized with no significant changes in basolateral membrane potential or EMF. It is concluded that: (a) apical Na conductance depends, in part, on the anionic composition of the mucosal solution, (b) there is a Cl- conductance in the apical membrane, and (c) the electrical communication between apical and basolateral membranes previously described is mediated by changes in the size of the cell Na pool, most likely by a change in sodium activity

Simulación de sistemas de riego hibridos FV-RED: aplicación a riego directo

CIES2020 - XVII Congresso Ibérico e XIII Congresso Ibero-americano de Energia SolarRESUMEN: Este artículo presenta la metodología utilizada en una herramienta de simulación de la productividad de sistemas de riego híbridos fotovoltaico-red, así como su aplicación a un sistema de riego directo en Marrakech, Marruecos. Se trata de una finca de olivar intensivo, cuyas necesidades de riego son 8 horas diarias entre marzo y octubre. La aportación fotovoltaica en ese periodo es de 1456 kWh/kWp, mientras que la red eléctrica tiene que aportar 66 kWh/kWp. Entre los meses de noviembre y febrero toda la energía fotovoltaica es desaprovechada (550 kWh/kWp) puesto que no se riega. Con el objetivo de generalizar el estudio, se analiza la influencia de las necesidades de riego diarias en la aportación FV mediante cuatro simulaciones adicionales para necesidades de riego diarias de 4 h, 10 h, 12 h y 16 h. Por ejemplo, en el mes de junio, y considerando 4 h de riego al día, la aportación FV es 104 kWh/kWp (cuando para las 8 h es 185 kWh/kWp), llegando a 239 kWh/kWp a partir de las 12 h de riego al día.ABSTRACT: This article explains the methodology used in a hybrid photovoltaic-grid irrigation system simulation tool, as well its application to a direct pumping system in Marrakech, Morocco. It is an intensive olive tree cultivation, with a daily irrigation need of 8 hours between March and October. The photovoltaic energy used in this period is 1456 kWh/kWp, while the grid electricity consumption is 66 kWh/kWp. Between November and February, the photovoltaic energy is wasted (550 kWh/kWp). To evaluate the influence of the irrigation needs in terms of the number of irrigation hours per day, four additional simulations were performed – for 4 h, 10 h, 12 h, and 16 h. For example, in June, and considering 4 h of irrigation per day, the photovoltaic energy used is 104 kWh/kWp (while it is 185 kWh/kWp for 8 hours), achieving 239 kWh/kWp from 12 hours of irrigation per day.info:eu-repo/semantics/publishedVersio

Sobre el número de módulos fotovoltaicos en serie para aplicaciones de riego

En sistemas de riego fotovoltaico la tensión mínima en el bus de continua del variador de frecuencia (VF) es impuesta por la tensión necesaria a la entrada de la moto-bomba. Así, siempre que esta tensión es más grande que la tensión del punto de máxima potencia del generador fotovoltaico parte de la energía que este podría entregar no se utiliza. El objetivo de este trabajo es estudiar estas pérdidas para 20, 21 y 22 módulos en serie (para módulos de 60 células en serie). Se puede concluir que si no hay caídas de tensión entre el VF y la moto-bomba las pérdidas son depreciables. Sin embargo, el aumento de estas pérdidas lleva a un incremento del porcentaje de pérdidas en energía fotovoltaica. Además, se verifica un aumento de las pérdidas con el incremento de la temperatura de célula

Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE trial and meta-analysis

BACKGROUND AND PURPOSE: Chronic kidney disease with reduced estimated glomerular filtration rate or elevated albuminuria increases risk for ischemic and hemorrhagic stroke. This study assessed the effects of sodium glucose cotransporter 2 inhibitors (SGLT2i) on stroke and atrial fibrillation/flutter (AF/AFL) from CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) and a meta-Analysis of large cardiovascular outcome trials (CVOTs) of SGLT2i in type 2 diabetes mellitus. METHODS: CREDENCE randomized 4401 participants with type 2 diabetes mellitus and chronic kidney disease to canagliflozin or placebo. Post hoc, we estimated effects on fatal or nonfatal stroke, stroke subtypes, and intermediate markers of stroke risk including AF/AFL. Stroke and AF/AFL data from 3 other completed large CVOTs and CREDENCE were pooled using random-effects meta-Analysis. RESULTS: In CREDENCE, 142 participants experienced a stroke during follow-up (10.9/1000 patient-years with canagliflozin, 14.2/1000 patient-years with placebo; hazard ratio [HR], 0.77 [95% CI, 0.55-1.08]). Effects by stroke subtypes were: ischemic (HR, 0.88 [95% CI, 0.61-1.28]; n=111), hemorrhagic (HR, 0.50 [95% CI, 0.19-1.32]; n=18), and undetermined (HR, 0.54 [95% CI, 0.20-1.46]; n=17). There was no clear effect on AF/AFL (HR, 0.76 [95% CI, 0.53-1.10]; n=115). The overall effects in the 4 CVOTs combined were: Total stroke (HRpooled, 0.96 [95% CI, 0.82-1.12]), ischemic stroke (HRpooled, 1.01 [95% CI, 0.89-1.14]), hemorrhagic stroke (HRpooled, 0.50 [95% CI, 0.30-0.83]), undetermined stroke (HRpooled, 0.86 [95% CI, 0.49-1.51]), and AF/AFL (HRpooled, 0.81 [95% CI, 0.71-0.93]). There was evidence that SGLT2i effects on total stroke varied by baseline estimated glomerular filtration rate (P=0.01), with protection in the lowest estimated glomerular filtration rate (45 mL/min/1.73 m2]) subgroup (HRpooled, 0.50 [95% CI, 0.31-0.79]). CONCLUSIONS: Although we found no clear effect of SGLT2i on total stroke in CREDENCE or across trials combined, there was some evidence of benefit in preventing hemorrhagic stroke and AF/AFL, as well as total stroke for those with lowest estimated glomerular filtration rate. Future research should focus on confirming these data and exploring potential mechanisms

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to 300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m 2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to &lt;90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], &gt;300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of &lt;15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P&lt;0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P&lt;0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years